| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B Bontempi, K T Whelan, V B Risbrough, T S Rao, J J Buccafusco, G K Lloyd, F Menzagh. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates. The Journal of pharmacology and experimental therapeutics. vol 299. issue 1. 2001-10-18. PMID:11561092. |
preclinical and clinical data have suggested the potential use of nicotinic acetylcholine receptor (nachr) ligands for treating cognitive dysfunction associated with neurodegenerative diseases, such as alzheimer's disease. |
2001-10-18 |
2023-08-12 |
mouse |
| Y J Liou, I C Lai, C J Hong, H C Liu, T Y Liu, S J Tsa. Association analysis of the partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant and Alzheimer's disease. Dementia and geriatric cognitive disorders. vol 12. issue 5. 2001-09-27. PMID:11455129. |
we tested the hypothesis that the allelic variant, 2bp deletion, of the partially duplicated alpha7 nachr gene confers susceptibility to alzheimer's disease. |
2001-09-27 |
2023-08-12 |
Not clear |
| R T Rei, M N Sabbagh, J Corey-Bloom, P Tiraboschi, L J Tha. Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. Neurobiology of aging. vol 21. issue 5. 2001-01-18. PMID:11016544. |
we sought to delineate differences between alpha7 nicotinic acetylcholine receptor (nachr) levels in alzheimer's disease (ad), dementia with lewy bodies (dlb) and age matched controls, as well as the correlations between alpha7 or non-alpha7 nachr levels and synaptophysin (syn) or choline acetyltransferase (chat) in dlb. |
2001-01-18 |
2023-08-12 |
Not clear |
| E Hellström-Lindahl, J A Cour. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behavioural brain research. vol 113. issue 1-2. 2001-01-03. PMID:10942042. |
by contrast no loss in nachr binding with aging is observed in the thalamus and only after the 70th decade in the striatum, although in alzheimer's disease, parkinson's disease and lewy body dementia deficits in nachrs are observed in these areas and may be associated with specific disease-related processes. |
2001-01-03 |
2023-08-12 |
human |
| A Maelicke, A Schrattenholz, M Samochocki, M Radina, E X Albuquerqu. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behavioural brain research. vol 113. issue 1-2. 2001-01-03. PMID:10942046. |
one of the most prominent cholinergic deficit in alzheimer's disease (ad) is the reduced number of nicotinic acetylcholine receptors (nachr) in the hippocampus and cortex of ad patients, as compared to age-matched controls. |
2001-01-03 |
2023-08-12 |
human |
| N D Cosford, L Bleicher, J M Vernier, L Chavez-Noriega, T S Rao, R S Siegel, C Suto, M Washburn, G K Lloyd, I A McDonal. Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist. Pharmaceutica acta Helvetiae. vol 74. issue 2-3. 2000-08-09. PMID:10812948. |
the discovery that neuronal nachrs are further subdivided into multiple subtypes suggests that drugs which act selectively at specific nachr subtypes might effectively treat parkinson's disease (pd), alzheimer's disease (ad), schizophrenia, adhd, depression, anxiety or pain without the accompanying adverse side effects associated with non-selective agents such as nicotine (1) and epibatidine. |
2000-08-09 |
2023-08-12 |
human |
| E Hellström-Lindahl, H Moore, A Nordber. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. Journal of neurochemistry. vol 74. issue 2. 2000-02-10. PMID:10646530. |
several cholinesterase inhibitors used in the treatment of alzheimer's disease (ad) have been shown to interact with an allosteric site on the nicotinic acetylcholine receptor (nachr). |
2000-02-10 |
2023-08-12 |
Not clear |
| O K Steinlein, J Stoodt, R A de Vos, E N Steur, A Wevers, U Schütz, H Schröde. Mutation screening of the CHRNA4 and CHRNB2 nicotinic cholinergic receptor genes in Alzheimer's disease. Neuroreport. vol 10. issue 14. 2000-01-04. PMID:10549797. |
mutation screening of the chrna4 and chrnb2 nicotinic cholinergic receptor genes in alzheimer's disease. |
2000-01-04 |
2023-08-12 |
Not clear |
| A Wevers, L Monteggia, S Nowacki, W Bloch, U Schütz, J Lindstrom, E F Pereira, H Eisenberg, E Giacobini, R A de Vos, E N Steur, A Maelicke, E X Albuquerque, H Schröde. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. The European journal of neuroscience. vol 11. issue 7. 1999-07-30. PMID:10383644. |
in order to elucidate the underlying cause of this cholinoceptive dysfunction, the expression of two pharmacologically different nicotinic acetylcholine receptor (nachr) subunits (alpha4, alpha7) was studied in the cerebral cortex of alzheimer patients as compared to controls. |
1999-07-30 |
2023-08-12 |
human |
| E Hellström-Lindahl, M Mousavi, X Zhang, R Ravid, A Nordber. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain research. Molecular brain research. vol 66. issue 1-2. 1999-05-13. PMID:10095081. |
the regional expression of mrna for the nicotinic acetylcholine receptor (nachr) subunits alpha3, alpha4 and alpha7 was examined in postmortem brain tissues from controls and patients with alzheimer's disease (ad) by using quantitative rt-pcr. |
1999-05-13 |
2023-08-12 |
human |
| A Marutle, U Warpman, N Bogdanovic, L Lannfelt, A Nordber. Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. Journal of neurochemistry. vol 72. issue 3. 1999-03-18. PMID:10037489. |
significant reductions in numbers of nachrs were observed in various cortical regions of the swedish 670/671 app mutation family subjects (-73 to -87%) as well as in sporadic alzheimer's disease (ad) cases (-37 to -57%) using the nicotinic agonists [3h]epibatidine and [3h]nicotine, which bind with high affinity to both alpha3 and alpha4 and to alpha4 nachr subtypes, respectively. |
1999-03-18 |
2023-08-12 |
human |
| U Warpman, A Nordber. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport. vol 6. issue 17. 1996-09-24. PMID:8747166. |
selective losses in the major population of nachr were observed in the temporal cortex of brains from individuals with alzheimer's disease with all three agonists. |
1996-09-24 |
2023-08-12 |
human |
| U Warpman, A Nordber. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport. vol 6. issue 17. 1996-09-24. PMID:8747166. |
this suggested that the alpha 4 beta 2 nachr subunit might be the most vulnerable in alzheimer's disease (ad) and a possible target for therapeutic strategies. |
1996-09-24 |
2023-08-12 |
human |